DKCM
TNXP icon

Davidson Kempner Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Davidson Kempner Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-90,006
Closed -$1.41M – 264
2025
Q4 		$1.41M Buy
+90,006
New +$1.66M 0.02% 163

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Davidson Kempner Capital Management's TNXP Position: Q1 2026 in Review

Davidson Kempner Capital Management sold out of Tonix Pharmaceuticals (TNXP) in Q1 2026, closing a stake of 90,006 shares — an estimated $1.41M sold.

Davidson Kempner Capital Management first reported a position in TNXP in Q4 2025 and held it in 1 quarter. The position peaked at $1.41M in Q4 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Davidson Kempner Capital Management reported no remaining Tonix Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Davidson Kempner Capital Management sold 90,006 Tonix Pharmaceuticals shares in Q1 2026, an estimated $1.41M.
  • Davidson Kempner Capital Management first reported a position in Tonix Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Davidson Kempner Capital Management's Tonix Pharmaceuticals position peaked at $1.41M in Q4 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Davidson Kempner Capital Management's 13F filing for Q1 2026, filed 15 May 2026.